文献速递脑血管病

替格瑞洛联合阿司匹林预防急性缺血性卒中或TIA致残性卒中

Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-11-07

IMPORTANCE: Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke.…

要点

  • 替格瑞洛加阿司匹林较单用阿司匹林降低30天致残性卒中或死亡风险。
  • 复发卒中患者的mRS序贯分析显示替格瑞洛组残疾负担更轻。
  • 基线NIHSS 4-5分、同侧狭窄≥30%等与残疾相关。

核心结论

  • 在TIA和小型缺血性卒中患者中,替格瑞洛加阿司匹林在预防30天致残性卒中或死亡方面优于单用阿司匹林,并减少了缺血性卒中复发导致的总残疾负担。

主要发现

  • 与残疾相关的因素包括基线NIHSS 4-5分、同侧狭窄至少30%、亚洲种族/族裔、高龄和较高的收缩压,替格瑞洛治疗与较少残疾相关。

临床怎么用

  • 对非心源性非重症缺血性卒中或高危TIA患者,可考虑在阿司匹林基础上加用替格瑞洛以降低30天致残性卒中或死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke. OBJECTIVE: To evaluate the superiority of ticagrelor added to aspirin in preventing disabling stroke and to understand the factors associated with recurrent disabling stroke. DESIGN, SETTING, AND PARTICIPANTS: The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) was a randomized clinical trial conducted between January 22, 2018, and December 13, 2019, with a 30-day follow-up, at 414 hospitals in 28 countries. The trial included 11 016 patients with a noncardioembolic, nonsevere ischemic stroke or high-risk TIA, including 10 803 with modified Rankin Scale score (mRS) recorded at 30 days. INTERVENTIONS: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo within 24 hours of symptom onset. All patients received aspirin, 300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30. MAIN OUTCOMES AND MEASURES: Time to the occurrence of disabling stroke (progression of index event or new stroke) or death within 30 days, as measured by mRS at day 30. Disabling stroke was defined by mRS greater than 1. RESULTS: Among participants with 30-day mRS greater than 1, mean age was 68.1 years, 1098 were female (42.6%), and 2670 had an ischemic stroke (95.8%) as a qualifying event. Among 11 016 patients, a primary end point with mRS greater than 1 at 30 days occurred in 221 of 5511 patients (4.0%) randomized to ticagrelor and in 260 of 5478 patients (4.7%) randomized to placebo (hazard ratio [HR], 0.83; 95% CI, 0.69-0.99, P = .04). A primary end point with mRS 0 or 1 at 30 days occurred in 70 of 5511 patients (1.3%) and 87 of 5478 patients (1.6%) (HR, 0.79; 95% CI, 0.57-1.08; P = .14). The ordinal analysis of mRS in patients with recurrent stroke showed a shift of the disability burden following a recurrent ischemic stroke in favor of ticagrelor (odds ratio, 0.77; 95% CI, 0.65-0.91; P = .002). Factors associated with disability were baseline National Institutes of Health Stroke Scale score 4 to 5, ipsilateral stenosis of at least 30%, Asian race/ethnicity, older age, and higher systolic blood pressure, while treatment with ticagrelor was associated with less disability. CONCLUSIONS AND RELEVANCE: In patients with TIA and minor ischemic stroke, ticagrelor added to aspirin was superior to aspirin alone in preventing disabling stroke or death at 30 days and reduced the total burden of disability owing to ischemic stroke recurrence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03354429.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Amarenco P, Denison H, Evans SR, et al. Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 33159526. doi:10.1001/jamaneurol.2020.4396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。